Table 2.
Clinicopathologic characteristics of PDAC patients UICC stage II with different adjuvant chemotherapy response
| Total | PDAC II w/o CTX | PDAC II w CTX | P | P | ||
|---|---|---|---|---|---|---|
| Good response | Bad response | |||||
| (n = 91) | I (n = 27) | II (n = 25) | III (n = 39) | II vs. III | ||
| Age (years) | ||||||
| ≤65 | 41 | 10 | 12 | 19 | 0.5092 | 1 |
| median (range) | 63 (54–65) | 56 (41–64) | 53 (31–65) | |||
| >65 | 50 | 17 | 13 | 20 | ||
| median (range) | 72 (66–84) | 73 (66–84) | 71 (67–79) | |||
| Gender | ||||||
| Female | 41 | 14 | 11 | 16 | 0.6801 | 1 |
| Male | 50 | 13 | 14 | 23 | ||
| UICC stage | ||||||
| IIa | 29 | 7 | 9 | 13 | 0.6469 | 1 |
| IIb | 62 | 20 | 16 | 23 | ||
| Grading | ||||||
| G1 | 5 | 0 | 3 | 2 | 0.0231 | 0.5008 |
| G2 | 50 | 10 | 16 | 24 | ||
| G3 | 36 | 17 | 6 | 13 | ||
| Perineural invasion | ||||||
| Pn0 | 32 | 10 | 10 | 12 | 0.7305 | 0.5904 |
| Pn1 | 59 | 17 | 15 | 27 | ||
| Vene invasion | ||||||
| V0 | 74 | 23 | 22 | 29 | 0.3256 | 0.2204 |
| V1 | 17 | 4 | 3 | 10 | ||
| Lymphatic invasion | ||||||
| L0 | 50 | 17 | 15 | 18 | 0.3367 | 0.3149 |
| L1 | 41 | 10 | 10 | 21 | ||
| Resection margin | ||||||
| R0 | 67 | 20 | 21 | 26 | 0.3071 | 0.1553 |
| R1 | 24 | 7 | 4 | 13 | ||
| Type of surgery | ||||||
| Pancreatic head resection | 75 | 26 | 17 | 32 | 0.0276 | 0.2347 |
| Traverso-Longmire | 66 | 22 | 15 | 29 | ||
| Whipple-Kausch | 9 | 4 | 2 | 3 | ||
| Pancreatic left resection | 16 | 1 | 8 | 7 | ||
| Adjuvant gemcitabine | ||||||
| Yes | 64 | 0 | 25 | 39 | 0.0000 | 1 |
| No | 27 | 27 | 0 | 0 | ||
| Tumor recurrence | ||||||
| ≤18 months | 63 | 24 | 0 | 39 | 0.0000 | 0.0001 |
| >18 months | 5 | 2 | 3 | 0 | ||
| Tumor related death | ||||||
| ≤18 months | 39 | 20 | 0 | 19 | 0.0234 | 0.0856 |
| >18 months | 22 | 6 | 3 | 13 | ||
p < 0.05 indicates significance